A federal magistrate judge has ordered AbbVie Inc. to promptly comply with an earlier command that it turn over documents related to an alleged campaign aimed at stymieing biosimilar competition to its $20 billion immunosuppressant Humira, warning against further efforts to throw “wrenches into the gears” of its high-stakes patent case against Boehringer Ingelheim International GmbH.

The Feb. 8 ruling, from U.S. Magistrate Judge Richard A. Lloret, came in response to Boehringer’s second set of production requests pertaining to its ”unclean hands” defense in Abbvie’s infringement suit, which accuses the German drugmaker of trying to illegally capitalize on Humira’s clinical success.